A mouse study testing the combined effects of a BACE inhibitor and plaque-clearing antibody builds new support for a combination strategy aimed at reducing Aβ buildup in people.
Could tweaking methodologies improve amyloid diagnosis and tracking?
Researchers are looking to the eye for a cheap, easy way to detect Alzheimer’s pathology in the brain.
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
Novartis Pharmaceuticals Corporation will partner with the Banner Alzheimer's Institute testing experimental preclinical therapies in the upcoming Alzheimer's Prevention Initiative ApoE4 study. The study complements the API ADAD trial.
Will an antibody signature make for a new Alzheimer’s diagnostic?
Tau and amyloid PET tracers demonstrate potential to sharpen the diagnosis of Alzheimer’s disease and frontotemporal dementias.
Researchers are increasingly branching out from their old focus on Aβ and tau to understand how these proteins intersect with physiological processes and new genetic regulatory mechanisms in the aging brain.
The overused adage of the fountain of youth rears its head again, as four new studies show how young blood rejuvenates old brain and muscle, pumping up the vasculature, stem cells, and restoring microglia’s appetite for waste products. Researcher are isolating the responsible factors, for example GDF11.
Do blood components really leak across an inflamed blood-brain barrier early on in the development of Alzheimer’s disease? Some GWAS hits and budding neuro-imaging and fluid markers are helping researchers find out.
Baby Boomers, keep your blood pressure down. Research is beginning to explain how even mild hypertension, a mid-life risk factor for late-life dementia, might be damaging the neurovascular unit.
Keystone presenters pulled out new tools to make connections between genetics and disease.
Keystone symposium highlights new strategies in the quest to find the biomarkers of Parkinson’s disease.
A Keystone symposium underscores the role of lysosomal dysfunction and vesicle trafficking in neurodegenerative disease.
Combination therapies may work where single drugs fall short, but testing them in AD may prove challenging.